News|Articles|November 17, 2026

FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma

Author(s)Chris Ryan
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • FDA labeling for liso-cel in LBCL no longer includes a limitation of use excluding patients with PCNSL.
  • The approved LBCL subtypes span DLBCL NOS (including transformed disease), high-grade B-cell lymphoma, PMBCL, and grade 3B follicular lymphoma.
SHOW MORE

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

The FDA has approved a label update for the indication for lisocabtagene maraleucel (Breyanzi; liso-cel) in large B-cell lymphoma (LBCL), removing the limitations of use for the CAR T-cell therapy in patients with primary central nervous system lymphoma (PCNSL).1

Liso-cel is approved for adult patients with LBCL, including diffuse LBCL (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:

  • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
  • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
  • relapsed or refractory disease after 2 or more lines of systemic therapy

Liso-cel is now the second CAR T-cell therapy to have its limitations of use removed for patients with PCNSL, following the FDA’s February 2026 approval of a label update for axicabtagene ciloleucel (Yescarta; axi-cel).2

How was liso-cel evaluated in second-line LBCL?

The indication for patients with refractory disease or relapse within 12 months of first-line chemoimmunotherapy is supported by the randomized, open-label, multicenter phase 3 TRANSFORM trial (NCT03575351).1

The trial enrolled patients who were candidates for HSCT, and 184 patients were randomly assigned 1:1 to receive liso-cel (n = 92) or standard therapy (n = 92), which comprised 3 cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in patients who achieved a complete response (CR) or partial response. Liso-cel was given at a target dose of 100 × 10⁶ CAR-positive viable T cells following lymphodepletion with fludarabine at 30 mg/m² per day and cyclophosphamide at 300 mg/m² per day for 3 days.

The primary end point was event-free survival (EFS) by independent review committee assessment.

Liso-cel produced a median EFS of 10.1 months (95% CI, 6.1-not reached) vs 2.3 months (95% CI, 2.2-4.3) with standard therapy (HR, 0.34; 95% CI, 0.22-0.52; one-sided P < .0001). The CR rates were 66% (95% CI, 56%-76%) vs 39% (95% CI, 29%-50%), respectively (P < .0001), and the respective median progression-free survivals were 14.8 months (95% CI, 6.6-not reached) vs 5.7 months (95% CI, 3.9-9.4; HR, 0.41; 95% CI, 0.25-0.66; P = .0001). Overall survival did not reach statistical significance at the interim analysis.

How was liso-cel evaluated in transplant-ineligible patients?

The indication for patients who are not eligible for HSCT after first-line chemoimmunotherapy is supported by the single-arm, open-label, multicenter phase 2 PILOT trial (NCT03483103). Patients were required to meet at least 1 criterion for transplant ineligibility, such as age of 70 years or older, an ECOG performance status of 2, or impaired pulmonary, cardiac, renal, or hepatic function. Patients received a planned dose of 100 × 10⁶ CAR-positive viable T cells following the same lymphodepletion regimen, and efficacy was based on CR rate by an independent review committee per Lugano 2014 criteria.

Among patients who received liso-cel (n = 61), the overall response rate (ORR) was 80% (95% CI, 68%-89%), including a CR rate of 54% (95% CI, 41%-67%). The median time to CR was 1 month (range, 0.8-6.9). The median duration of response (DOR) was 11.2 months (95% CI, 5.1-not reached) among all responders and was not reached (95% CI, 11.2-not reached) among patients who achieved a CR. Among all leukapheresed patients (n = 74), the ORR was 68% (95% CI, 56%-78%).

How was liso-cel evaluated in third-line and later LBCL?

The indication for patients with relapsed or refractory LBCL after 2 or more lines of systemic therapy is supported by the LBCL cohort of the open-label, multicenter, single-arm phase 1 TRANSCEND NHL 001 trial (NCT02631044). The trial allowed enrollment of patients with prior HSCT and secondary central nervous system (CNS) lymphoma involvement. Patients received liso-cel within a dose range of 50 to 110 × 10⁶ CAR-positive viable T cells following lymphodepletion with fludarabine and cyclophosphamide, in both inpatient and outpatient settings.

Among efficacy-evaluable patients (n = 192), the ORR was 73% (95% CI, 67%-80%), and the CR rate was 54% (95% CI, 47%-61%). The median DOR was 16.7 months (95% CI, 5.3-not reached) and was not reached (95% CI, 16.7-not reached) among patients with a best response of CR. The median time to first response was 1.0 months (range, 0.7-8.9).

What is the safety profile of liso-cel in LBCL?

The prescribing information for liso-cel carries a boxed warning for cytokine release syndrome (CRS), neurologic toxicities, and T-cell malignancies. Any-grade CRS occurred in 49% of patients in TRANSFORM (n = 89), 39% in PILOT (n = 61), and 46% in the TRANSCEND NHL 001 LBCL cohort (n = 268); grade 3 or higher CRS occurred in 1.1%, 1.6%, and 4.1%, respectively. Grade 3 or higher encephalopathy was reported in 4.9% of patients in PILOT and 9% of patients in TRANSCEND NHL 001.

Serious adverse effects (AEs) occurred in 38% of patients in TRANSFORM, 33% in PILOT, and 46% in TRANSCEND NHL 001, and fatal AEs occurred in 4% of patients in TRANSCEND NHL 001.1The most common AEs (≥20%) in TRANSFORM were fever, musculoskeletal pain, headache, fatigue, nausea, constipation, and dizziness. In PILOT, the most common AEs were fatigue, fever, nausea, encephalopathy, hypotension, musculoskeletal pain, and edema.

References

  1. Breyanzi. Prescribing information. Bristol Myers Squibb; 2026. Accessed November 17, 2026. https://packageinserts.bms.com/pi/pi_breyanzi.pdf
  2. FDA approves label update for Kite’s Yescarta for relapsed/refractory primary central nervous system lymphoma. News release. Kite. February 6, 2026. Accessed November 17, 2026. https://www.kitepharma.com/news/press-releases/2026/2/fda-approves-label-update-for-kites-yescarta-for-relapsedrefractory-primary-central-nervous-system-lymphoma

Related to this article